| Objective: To observe and evaluate the efficacy and safety of parecoxib in clinic application of cystoscopy.Methods: In this prospective, randomized, single blind clinical trial, we selected the standard group randomly in the patients who accepted the cystoscope operation in our hospital from May, 2015 to September, 2015, and recorded them by A1, B1, C1 for female A2, B2, C2 for male, with 50 cases in each group, 300 cases in total. For A1(A2) group, 10 ml aseptic paraffin oil for lubrication and intramuscular injection of 2ml sterile saline were given 3 minutes before the operation and used as the negative control group. For B1(B2) group, 10 ml 1% tetracaine mucilage for surface mucosal anesthesia and intramuscular injection of 2ml sterile saline were given 3 minutes before the operation and used as the positive control group. For C1(C2) group, 10 ml aseptic paraffin oil for lubrication and intramuscular injection of 40 mg parecoxib were given 3 minutes before the operation and used as the experimental group. We recorded the preoperative, intraoperative and postoperative arterial pressure and heart rate changes, the operation time, observe the incidence of agitation rate of patients by cystoscopy stimulates, recorded the VAS score checked by their own pain 10 minutes after the operation, followed up the postoperative urethral pain at 12 h and 24h; observed the dizziness, pruritus, nausea and other obvious adverse reactions after operation.Results: To compare with the negative control group(paraffin oil group+NS), the application of parecoxib and tetracaine both can decrease VAS score evaluated by themselves and doctor for female patients who accepted outpatient cystoscopy, and the difference had statistical significance(P < 0.05). The ratio of pain in the urethra at 12 h and 24 h were similar for parecoxib group and tetracaine group, and there was no significant difference. Similarly, it showed a same effect in male patients with the application of parecoxib about the VAS score, and the difference was also statistically significant(P < 0.05), so the analgesic effect of parecoxib was obvious. Otherwise, tetracaine decreased the VAS score without a statistical significance(P >0.05). The ratio of patients with pain in the urethra at 12 h had no significant difference between parecoxib group and tetracaine group, but the parecoxib group was significantly lower than that of the tetracaine group at 24h; furthermore, the moderate pain percentage and the second operation rejection ratio of parecoxib group were significantly better than both of the tetracaine group and negative control group.Conclusion: The application of parecoxib in ambulatory cystoscopy can decrease VAS score of patients, reduce pain, it had a better analgesic effect than tetracaine especially for male patients, and showed a preemptive analgesic effect which can improve the satisfaction of patients and make it safe and feasible. |
